Ginkgo Inc (DNA:NYE) (Soaring Eagle Acquisition Corp) Analyst rate as a Buy, $8 target

In September 2021, Soaring Eagle Acquisition merged with Ginkgo Bioworks, and the company was delisted from the stock market.  Soaring Eagle now essentially trades under the Ginkgo Bioworks label.

The SPAC merger resonates having Ginkgo Bioworks maintaining its current management team, but Soaring Eagle’s CEO Harry Sloan joins the company’s Board. Also several members of Soaring Eagle have also taken prominent positions in the newly merged company.

Ginkgo Bioworks Holdings Stock Analysis:

Based on the Ginkgo Bioworks Holdings stock forecasts from 6 analysts, the average analyst target price for Ginkgo Bioworks Holdings is USD 8.44 over the next 12 months. Ginkgo Bioworks Holdings’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Ginkgo Bioworks Holdings is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Ginkgo Bioworks Holdings’s stock price was USD 3.23Ginkgo Bioworks Holdings’s stock price has changed by +35.71% over the past week, +14.54% over the past month and 0% over the last year.

Recent Analyst Ratings:

What we like:

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What we don’t like:

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector